$750.00 – $14,100.00
$500.00 – $6,800.00
Rapid Alpha-Pseudoviruses for Coronavirus Research
NEW! SARS-CoV-2 EG.5.1 and BA.2.86 variant particles are now available!
Product Description
Product Description
Rapid alpha-pseudovirus for SARS-CoV-2, SARS-CoV and MERS-CoV
Applications:
- Screening and quantification of anti-coronavirus-neutralizing antibodies
- Anti-coronavirus drug screening
- Quantification of viral mutants’ infectivity
- Identification of host co-factors and restriction factors of coronaviruses
Major advances:
- Faster speed – As fast as 6 hours for the detection of reporter expression for Ha-CoV-2 versus 2-3 days for S protein pseudotyped lentivirus.
- More robust reporter signal – Advantage of the rapid and robust gene expression capacity of alphavirus vector for reporter expression.
- High fidelity in particle structure – Contains all 4 SARS-CoV-2 structural proteins (S, M, E, and N), but no structural proteins from other viruses. In contrast, lenti- and VSV- pseudoviruses contain only the S protein from SARAS-CoV-2, and multiple structural proteins from other viruses, such as HIV-1 Gag and Pol.
- Strong correlation (coefficient value r2 = 0.87) with wild-type SARS-CoV-2 in neutralizing antibody assays (Hetrick et al., 2020).
Virongy offers pre-assembled Ha-CoV-2 and other coronaviral alpha-pseudovirus particles. We also help customers to perform antiviral drug screening and quantification of neutralizing antibodies. For more information, please contact us by email: info@virongy.com
Description:
The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirus-based vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle.
Ha-CoV-2 represents a major technological advancement in the development of SARS-CoV-2 pseudoviruses and serves as a platform for rapid and robust quantification of neutralizing antibodies, viral mutants, and antiviral drugs (Dabbagh et al., 2021; He et al., 2021). Virongy has now expanded its library of rapid alpha-pseudoviruses to other viruses within the coronavirus family.
Fig. 2. Comparison of Ha-CoV-2 with S protein pseudotyped lentivirus in a time course of infection and reporter expression.
HEK293T(ACE2/TMPRESS2) cells were used as the target cell.
Fig. 3. Neutralizing antibody activity measured with Ha-CoV-2(Luc).
50 μl of Ha-CoV-2(Luc) (Cat# HaCoV2Luc-01) was incubated with serially diluted anti-serum for 1 hour at 37°C. The virus-antibody complex was used to infect 4×105 HEK293T(ACE2/TMPRSS2) target cells in a 96-well plate. Luciferase assay was performed at 12 hours post-infection. Coronavirus alpha-pseudoviruses, Coronavirus alpha-pseudoviruses, Coronavirus alpha-pseudoviruses
Cornavirus alpha-pseudoviruses
Example of product Certificate of Analysis
Ha-CoV-2 is intended for Research Use Only and is not for diagnostic or therapeutic purposes or uses in humans or animals.
SARS-CoV-2 Variants Available
SARS-CoV-2 Variants Available
Documentation
Documentation
Alpha Pseudovirus – MSDS
Alpha Pseudovirus – Handbook
Suggested protocol
(For the infection of target cells in a 12-well plate. For more protocol details in other formats, such as in 96-well plate, please contact info@virongy.com)
Count target cells, g. HEK293T(ACE2/TMPRSS2), to be infected, and seed 1 x 105 cells per well in 0.5 ml culture medium in each well of a 12-well plate. Culture cells overnight. Note: Cell viability should be ≥ 80%.
Before infection, remove the medium, and add 300 μl fresh medium.
Add 100 μl Ha-CoV-2 virus, and infect for 2-6 hours. *
Wash cells by adding 1 ml fresh medium.
After washing, add 1 ml fresh complete medium (DMEM + 10% FBS).
Culture cells for 12-18 hours to read signals (e.g. luciferase assay).
* if performing neutralizing antibody assays, incubate the virus with antibodies at 37°C for 1 hour, then add the virus-antibody complex to cells for infection.
